(NOT LEGAL ADVICE) patent and licensing information relevant to clean energy, biotechnology and pharmaceuticals for business development.
http://biotechpharmacleanenergypatents.blogspot.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.2 seconds
16x16
32x32
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
0
SITE IP
172.217.6.65
LOAD TIME
0.2 sec
SCORE
6.2
Biotech/ Pharma/ GreenTech/ Patent Blog | biotechpharmacleanenergypatents.blogspot.com Reviews
https://biotechpharmacleanenergypatents.blogspot.com
(NOT LEGAL ADVICE) patent and licensing information relevant to clean energy, biotechnology and pharmaceuticals for business development.
biotechpharmacleanenergypatents.blogspot.com
Biotech/ Pharma/ GreenTech/ Patent Blog: Hoffman-LaRoche Agrees to Permanent Injunction for its Pegylated EPO Mircera® Product In Amgen Litigation
http://biotechpharmacleanenergypatents.blogspot.com/2009/12/hoffman-laroche-agrees-to-permanent.html
Wednesday, December 23, 2009. Hoffman-LaRoche Agrees to Permanent Injunction for its Pegylated EPO Mircera Product In Amgen Litigation. After an appeal to, and remand by, the Federal Circuit, the new settlement agreement (December 21, 2009) provides no payments to Amgen, but Roche can now launch as of the date of the last to expire Amgen EPO patents, on July 1, 2014. Claims 1 and 2;. Claims 3, 7-8. Claim 7; and. The Federal Circuit had affirmed most of the determinations by the District Court, but vacate...
Biotech/ Pharma/ GreenTech/ Patent Blog: New EPO Rules relating to Divisional/Amendment/Responses to PCT and EPO Preliminary Search/Opinions: APPLICANTS BEWARE!
http://biotechpharmacleanenergypatents.blogspot.com/2010/02/new-epo-rules-relating-to.html
Monday, February 22, 2010. New EPO Rules relating to Divisional/Amendment/Responses to PCT and EPO Preliminary Search/Opinions: APPLICANTS BEWARE! In what looks like the EPO's response to the USPTO's previous attempts to change continuation and divisional practice and limit claims, the EPO, in its March 25 2009 decision, has issued amended rules 36(1) and (2), 57(a) and 135(2) EPC that go into effect April 1, 2010. As well as new claim fees that effectively limit the number of claims in an application.
Biotech/ Pharma/ GreenTech/ Patent Blog: US Senate Passes 2011 Patent Reform Act S23
http://biotechpharmacleanenergypatents.blogspot.com/2011/03/us-senate-passes-2011-patent-reform-act.html
Thursday, March 10, 2011. US Senate Passes 2011 Patent Reform Act S23. The US Senate Tuesday (March 8, 2011) passed S23, the Patent Reform Act, that if passed by the House will make the first major changes to the US patent system since the adoption of the GATT treaty in 1995 that changed the patent term to 20 years from earliest priority date. Major aspects of the bill include:. 1 First to file system. That grants priority between different applicants on earliest date of filing a patent application.
Biotech/ Pharma/ GreenTech/ Patent Blog: In re BP Lubricants: False Marking Restricted, S23 May Eliminate Qui Tam Actions
http://biotechpharmacleanenergypatents.blogspot.com/2011/03/in-re-bp-lubricants-false-marking.html
Friday, March 25, 2011. In re BP Lubricants: False Marking Restricted, S23 May Eliminate Qui Tam Actions. The Federal Circuit (CAFC) ( Opinion. 8220;merely creates a rebuttable presumption of intent to deceive. . .”. 8220; ‘ the inference of intent to deceive cannot be defeated with blind assertions of good faith where the patentee has knowledge of mismarking.’ “. 8220;Upon information and belief:”. 8220;(1) BP is a sophisticated company and has experience applying for, obtaining and litigating patents;.
Biotech/ Pharma/ GreenTech/ Patent Blog: Practical Effects of the Supreme Court's Recent Bilski Decision
http://biotechpharmacleanenergypatents.blogspot.com/2010/07/practical-effects-of-supreme-courts.html
Sunday, July 11, 2010. Practical Effects of the Supreme Court's Recent Bilski Decision. On June 28, 2010, the Supreme Court decided Bilski v. Kappos (Slip op.08–964), rejecting the attempt by the Federal Circuit's en banc court to reject it's own prior State Street patentable subject matter test (State Street Bank and Trust Co v. Signature Financial Group, Inc., 149 F. 3d 1368, 1373), and provide a new, exclusive "machine or transformation" test. Subscribe to: Post Comments (Atom). Author and contact info.
TOTAL PAGES IN THIS WEBSITE
20
biotechpharma.eu
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Home — Biotechpharma
Development and Manufacturing of Biopharmaceuticals. Contract Research and Development of Recombinated Proteins. Development and Manufacturing of Biopharmaceuticals. Upstream Process Development (USP). Downstream Process Development (DSP). Manufacturing of drug substance. Manufacturing of drug product. Phone: 370 5255 9140.
biotechpharma.net - This website is for sale! - biotechpharma Resources and Information.
Bio-Tech Pharmacal | Vitamins, Supplements, Vitamin D
Blog / Press Release. Bio-Tech Pharmacal supports the Broyles Foundation. Mission by donating 5% of Vitamin D3-5 sales. Healthy weight for longevity! Bio-Tech Pharmacal is donating Vitamin D3 to the Vitamin D Council. Spreading vitamin D deficiency awareness, a worldwide problem! Bio-Tech Pharmacal donates vitamin D3 to GrassrootsHealth. Free Shipping on Orders Over $100! Featured Vitamins and Supplements. Doctor's Corner Jeff Baker, M.D. Fatty liver-an epidemic for mid-life Americans. We utilize scienti...
biotechpharmaceutical.com domain name is for sale. Inquire now.
This premium domain name is available for purchase! Your domain name is your identity on the Internet. Establish instant trust and credibility with customers. Premium domain names appreciate in value over time. Boost your business and invest in the right domain name.
biotechpharmacleanenergypatents.blogspot.com
Biotech/ Pharma/ GreenTech/ Patent Blog
Friday, March 25, 2011. In re BP Lubricants: False Marking Restricted, S23 May Eliminate Qui Tam Actions. The Federal Circuit (CAFC) ( Opinion. 8220;merely creates a rebuttable presumption of intent to deceive. . .”. 8220; ‘ the inference of intent to deceive cannot be defeated with blind assertions of good faith where the patentee has knowledge of mismarking.’ “. 8220;Upon information and belief:”. 8220;(1) BP is a sophisticated company and has experience applying for, obtaining and litigating patents;.
biotechpharmaclinico.com
The Sponsored Listings displayed above are served automatically by a third party. Neither the service provider nor the domain owner maintain any relationship with the advertisers. In case of trademark issues please contact the domain owner directly (contact information can be found in whois).
Buy Viagra Cialis Levitra Propecia online fast delivery
Effective way to treat your disease. Buy Viagra Cialis Levitra Propecia online fast delivery. Welcome to biotechpharmacy.com. Welcome to biotechpharmacy.com, the online website offering high quality treatments such as Viagra, Cialis, Levitra etc…. The only prescription treatment against overweight and obesity: Orlistat Xenical from Roche. The only drug against premature ejaculation: Priligy from Janssen-Cilag laboratories. Levitra helps control impotence by relaxing the blood vessels in the penis to enco...
Biotech labs
Box Types Boxes for Shipping. Supplier Check Our Partners. Reseller Point For Reseller. Contact Write a Message. Welcome to Biotech labs which one of the best steroid product supplier! Click here to sell all product. We follow GMP like standards to ensure that best products are served. We use MILLIPORE and SARTORIUS. Filtering systems, Raw material suppliers were picked using Taiguisteroid. We believe BioTech lab. Would to be listed in one of the 10 best UG Labs in the world. YOUR BioTech LABS TEAM.
biotechpharmajobs.com - This website is for sale! - biotech pharma jobs Resources and Information.
The owner of biotechpharmajobs.com. Is offering it for sale for an asking price of 3497 USD! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
biotechpharmanews.wordpress.com
Biotech Pharma News | Just another WordPress.com site
Just another WordPress.com site. Weekly News Update (Apr 18 – Apr 23) on Biotech Pharma News (www.BiotechPharmaNews.com). April 25, 2011. Http:/ www.biotechpharmanews.com/news.html. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO). Saturday, 23 April 2011 06:14. Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB). Announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851.
